

Diagnosis and Management of Bipolar Disorder With Comorbid Anxiety in the Elderly

Martha Sajatovic, M.D., and Helen C. Kales, M.D.

Currently, in individuals over 65 year of age, prevalence rates of bipolar disorder range from 0.1% to 0.4%. As is the case for bipolar disorder in younger individuals, bipolar disorder may be unrecognized or underrecognized among older adults. While anxiety disorders are frequently comorbid among younger individuals with bipolar illness, the prevalence and impact of comorbid anxiety is far less understood among geriatric individuals with bipolar disorder, in whom anxiety disorders may be underreported. This comorbidity may have serious consequences, since in older adult populations with depression, the presence of comorbid anxiety is associated with more severe depressive symptoms, more chronic medical illness, greater functional impairment, and lower quality of life; the same associations may prove to be true in older patients with bipolar disorder. As with younger individuals with bipolar disorder, effective treatment of the underlying mood disorder is critically important before treating comorbid symptoms. Unfortunately, few evidence-based studies are available to guide the treating clinician in the management of these vulnerable patients, many of whom have additional psychiatric or medical comorbidity.

(J Clin Psychiatry 2006;67[suppl 1]:21–27)

The elderly are the fastest growing segment of the U.S. population, with a 12% increase in the number of persons 65 years and older from 1990 to 2000.¹ Additionally, over the next 3 decades, the number of individuals older than 85 years—the old old—is expected to more than double, with an estimated 8.9 million individuals by the year 2030.¹ Because of these changing demographic trends in the general population as well as greater sophistication in recognition and treatments for individuals with bipolar disorder, bipolar disorder in older adults has become a topic of increasing concern. Because the effects and impact of bipolar disorder are multidimensional, suffering and burden related to illness can be expected to affect not only the older adult with bipolar disorder but also his or her family and society at large. Clinicians struggling to meet the needs of geriatric patients with bipolar disorder have few evidence-based studies on which to base

treatment decisions and often must contend with issues of psychiatric and medical comorbidity in these vulnerable individuals. While anxiety disorders are frequently comorbid among younger individuals with bipolar illness, the prevalence and impact of comorbid anxiety is far less understood among geriatric individuals with bipolar disorder. Examining bipolar disorder and anxiety separately in this population may yield insight into the comorbid condition.

BIPOLAR DISORDER IN OLDER ADULTS

Prevalence

Currently, in individuals 65 years and older, prevalence rates of bipolar disorder range from 0.1% to 0.4%.² Hirschfeld and colleagues³ reported that 1.6% of individuals aged 55 to 64 years screened positive for bipolar disorder using the Mood Disorder Questionnaire (MDQ), as did 0.5% of individuals 65 years and older. As is the case for bipolar disorder in younger individuals, bipolar disorder may be unrecognized or underrecognized among older adults. Additionally, since the majority of older individuals with mental illness live in the community, samples from research studies may overemphasize inpatient populations with mania and provide limited information on bipolar depression and interepisode functioning among geriatric populations with bipolar disorder.⁴

Presentation

Among older adults, bipolar illness may be first manifested in young adulthood, persisting into later life, or alternatively may be of later onset. The proportion of “new” or later-onset cases of bipolar disorder among older indi-

From the Departments of Psychiatry and Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, Ohio (Dr. Sajatovic); the Department of Psychiatry, Section of Geriatric Psychiatry, University of Michigan; and the Geriatric Psychiatry Clinic, Serious Mental Illness Treatment Research and Evaluation Center (SMITREC) and Geriatric Research Education and Clinical Center, Department of Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Mich. (Dr. Kales).

This article is derived from the preliminary teleconference “The Recognition and Management of Bipolar Disorder With Comorbid Anxiety,” which was held June 2, 2005, and supported by an educational grant from Janssen Medical Affairs, L.L.C.

Corresponding author and reprints: Martha Sajatovic, M.D., Department of Psychiatry, University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, OH 44106 (e-mail: Martha.Sajatovic@uhhs.com).

viduals with bipolar disorder has been reported to range from 6.1% to 11.0%.⁵⁻⁸ It has been suggested that late-onset mania is a distinct subtype of bipolar disorder associated with medical and neurologic disorders.^{6,9,10} A recent analysis⁵ of a large database from the Veterans Health Administration (VHA) suggests that nearly one fourth of veterans with bipolar illness in the VHA are 60 years or older and that, of these, approximately 82.5% (N = 13,447) have early-onset illness.

Psychotic features occur in approximately 64% of older adults with bipolar disorder,¹¹ similar to what has been noted for mixed-age populations.⁹ Additionally, among older adults, cognitive impairment is also a particular concern. Multiple reports have suggested that individuals with bipolar disorder develop dementia at a higher-than-expected rate,¹²⁻¹⁴ but other data conflict with this finding.¹⁵ Depp and colleagues¹¹ recently noted that elderly bipolar patients have more cognitive and functional impairment compared with younger patients. Kessing and Nilsson¹⁴ found that the risk of dementia was significantly increased by the number of prior affective episodes. Finally, some older individuals may have bipolar symptoms that occur as a result of neurologic or medical pathology. The term *secondary mania* has been used to describe mania that occurs with identifiable medical or substance-related etiologies.¹⁶

Outcome

While outcomes of geriatric bipolar disorder seem to have improved significantly in the last several decades, primarily because of medication treatment advances,² geriatric bipolar disorder remains a condition associated with substantial morbidity and mortality. A recent study¹⁷ noted that older adults with bipolar disorder treated under standardized pharmacotherapy protocols had associated low symptom levels; however, most did not experience sustained recovery. In contrast to elderly adults with unipolar depression, in whom maintenance antidepressant pharmacotherapy is associated with sustained recovery in the majority of individuals,¹⁸ geriatric bipolar patients appear to have less stable outcomes and greater risk of relapse.¹⁷

With respect to longitudinal outcome, Angst and coworkers¹⁹ reported that at long-term follow-up (34 to 38 years), older adults with mood disorders had elevated mortality rates, primarily from suicide and circulatory disorders. In addition, manic patients over 65 years of age were reported to have more psychosocial deficits and poorer outcomes than similarly aged depressed patients and control participants.¹³ In a long-term Swiss study²⁰ of older bipolar patients (median age = 68 years), only 16% had fully recovered, 36% were still suffering from recurring episodes, and 7% had committed suicide.

In summary, geriatric bipolar disorder appears to have a pervasive effect on multiple domains of life functioning

across the life span. In addition to mania and depression, cognitive impairment may affect functional status as well.

ANXIETY IN LATER LIFE

Prevalence

Although geriatric anxiety is common, it has received less attention than other disorders.²¹ The reasons for this are several-fold: (1) despite their frequency in the community, primary anxiety disorders are not common in older patients seen in the mental health practice setting; (2) anxiety disorders seen in clinical practice are typically secondary to other disorders; (3) most older patients with anxiety do not meet criteria for specific disorders because existing diagnostic criteria may not adequately capture the quality of anxiety in the older patient; (4) primary anxiety disorders in the elderly generally have their onset in earlier adulthood and thus are usually chronic and have been present for decades; (5) given the absence of work or school responsibilities, older people may be more able to avoid anxiety-provoking situations than younger adults; and (6) ageist assumptions may hinder the detection and management of anxiety in later life (e.g., anxiety may be dismissed as "age-appropriate").^{21,22}

Despite this lack of attention, anxiety disorders as a group are the most common psychiatric disorders in older adults.²³ The prevalence of anxiety disorders in older community populations ranges from 2% to 10%, and the prevalence among older adults in institutional settings is higher.²⁴ Rates of clinically significant anxiety are even higher than rates of anxiety disorders, ranging from 24% in community samples²⁵ to 40% in hospitalized elderly.²⁶ Among the anxiety disorders, generalized anxiety disorder (GAD) and phobic disorders are the most prevalent, estimated at 2% to 7%²⁷⁻²⁹ and 3% to 10%,^{28,30} respectively. Panic disorder (estimated prevalence < 1%)^{27,28,30} and obsessive-compulsive disorder (OCD) (estimated prevalence < 2%)^{28,30} are less common than other anxiety disorders among older adults.

Presentation

The clinical presentation of anxiety in later life is impacted by a number of factors including (1) the presence of comorbidity, (2) masked symptoms, and (3) age at onset. Among older adults, anxiety disorders are frequently comorbid with each other and with other psychiatric and physical disorders. Such comorbidity may overlap with anxiety symptoms and make differential diagnosis more difficult.

Many anxiety disorders rarely occur as new-onset primary disorders in late life; when these disorders emerge, they are often secondary to psychiatric or medical comorbidity. Late-onset panic disorder may be less severe with patients having less distress due to body sensations, cognitions, or emotions during panic attacks.³¹ Early-onset post-

traumatic stress disorder (PTSD) may persist into late life, and new-onset PTSD may develop in older adults after traumatic events. Most older patients with GAD report an onset of symptoms in childhood or adolescence and appear to have a more severe course characterized by pathological worry compared with those with a late onset of symptoms.³² Late-life GAD is often concurrent with depression, though the onset and resolution of the 2 disorders may be distinct.³³

Anxiety Comorbid with Mood Disorders

Symptoms of anxiety are seen in as many as 65% of older patients with depression.³⁴ The most common anxiety disorders in older depressed patients are phobias and GAD, although comorbid panic attacks can also occur with depression.³⁵ Most new-onset GAD in older adults is thought to be “masked depression,” in which patients may emphasize anxiety symptoms or lack of pleasure without a sad mood^{22,36} or have unexplained or amplified physical symptoms. Beekman et al.³⁴ found that 47% of depressed older adults had a concurrent anxiety disorder, while Lenze and colleagues³⁷ found that 28% of depressed elderly had GAD and 23% of depressed elderly had other anxiety disorders. Given the considerable symptomatic overlap between GAD and depression; the high rates of mixed GAD, depression, and other anxiety disorders; and the frequent progression of GAD to depression over time,³⁸ Flint²¹ has noted that the usefulness of studying GAD as a discrete “pure” disorder in late life is questionable.

In older adult populations with depression, the presence of comorbid anxiety is associated with more severe depressive symptoms, more chronic medical illness, greater functional impairment, lower quality of life,³⁹ and greater suicidality.³⁵ Anxiety is also a risk factor for poor outcomes of late-life depression treatment, including non-adherence to treatment. In the recent PROSPECT study⁴⁰ using care management of late-life depression, the intervention was more effective than usual care in patients with low levels of anxiety but added little benefit for patients with higher anxiety severity. Older patients with anxious depression frequently misattribute somatic symptoms of anxiety to adverse medication effects,⁴¹ which contributes to both dropout and poor response in antidepressant trials.⁴² Additionally, older adults with an anxious/somatic focus may tend to discount psychological explanations for psychiatric symptoms and refuse treatment.⁴³

PREVALENCE OF COMORBID ANXIETY IN LATE-LIFE BIPOLAR DISORDER

Earlier reports have suggested that some types of comorbid conditions seen in younger bipolar populations may be less common among bipolar elders. For example, the rate of lifetime substance abuse in individuals with bi-

Table 1. Anxiety Disorder Comorbidity in Older Adults (aged 60 years and older) With Bipolar Disorder (N = 3748): Results From the VA Psychosis Registry, Federal Fiscal Year 2001^a

ICD-9 Code	Specific Anxiety Diagnosis	N	%
309.81	Prolonged posttraumatic stress disorder	1668	44.5
300.00	Anxiety state unspecified	1614	43.1
300.01	Panic disorder	220	5.9
300.02	Generalized anxiety disorder	867	23.1
300.09	Other anxiety states	145	3.9
300.10	Hysteria unspecified	5	0.1
300.20	Phobia unspecified	17	0.5
300.21	Agoraphobia with panic attacks	83	2.2
300.22	Agoraphobia without mention of panic attacks	17	0.5
300.23	Social phobia	20	0.5
300.29	Other isolated or simple phobias	9	0.2
300.3	Obsessive compulsive disorders	176	4.7

^aAdapted with permission from Blow.⁵¹

polar disorder over the age of 60 years has been reported as 13% to 30%, compared with a rate of 61% in mixed-age populations.^{4,5,44} Ponce et al.⁴⁵ reported that 29% of bipolar older adults had comorbid Axis I disorders; however, 2 recent and comprehensive publications that reviewed the current published literature on bipolar disorder in older adults^{4,46} noted an absence of studies that examined the presence of anxiety disorder in older people with bipolar disorder.

In mixed-age samples, it has been found that anxiety frequently coexists with bipolar disorder. In the National Comorbidity Survey,⁴⁷ 92% of those who met criteria for lifetime bipolar I disorder also met criteria for a lifetime anxiety disorder. In the Epidemiologic Catchment Area (ECA)⁴⁸ survey, 21% of bipolar I and II patients had lifetime panic disorder, which was significantly greater than in patients with major depression (10%) and in the total population (1%). Other studies⁴⁹ have confirmed that panic disorder and GAD occur at significantly higher rates among patients with bipolar disorder than unipolar depression. Similarly, 21% of the patients in the ECA survey with bipolar disorder had a lifetime diagnosis of OCD, compared with 12% of those with major depression and 2% of the general population.⁵⁰ ECA data also indicate that bipolar disorder more than quadruples the risk of social phobia (odds ratio = 4.6).⁵⁰

Research in older adults with bipolar disorder and comorbid anxiety disorders is needed to examine whether such disorders are epidemiologically comorbid with bipolar disorder. A recent analysis⁵¹ examined the recorded rates of comorbid psychiatric illness in a population of 16,330 geriatric patients with bipolar disorder in a VHA administrative database. Patients were identified from case registry files during federal fiscal year 2001. Table 1 identifies recorded anxiety diagnoses seen among the 3748 older veterans (60 years and older) with bipolar disorder and comorbid anxiety (23% of the total bipolar sample). We suspect the reported rates of anxiety found

are an underestimate of the true prevalence of clinically significant comorbid anxiety for the following reasons: (1) underreporting of comorbid anxiety disorder diagnoses in patients with a serious mental disorder diagnosis (bipolar disorder); (2) limited diagnostic precision in the sample by the case registry methodology, which used clinical diagnoses rather than standardized diagnostic assessments; and (3) the fact that many providers might not code subsyndromal anxiety or anxiety thought to be secondary to a primary mood disorder. Additional limitations include the gender homogeneity of the VHA sample and the overrepresentation of PTSD due to high combat exposure of the sample.

TREATMENT OF THE OLDER ADULT WITH BIPOLAR DISORDER AND COMORBID ANXIETY

Assessment and Foundational Treatment of Bipolar Disorder

A key component of appropriate and effective treatment of bipolar disorder in mixed populations is accurate diagnosis of illness. Accurate identification of elderly individuals with bipolar disorder may be complicated by the long duration of time between first depressive episode and first manic episode, which may occur relatively late in life. Young and Klerman⁵² reported that individuals with a history of major depression and family history of bipolar disorder (type V bipolar disorder) may develop type I or type II bipolar disorder with age. In a study⁵³ evaluating new-onset mania in older patients versus new-onset mania in younger patients, the older manic group had a longer latency from first depressive episode to first manic episode (17 years) compared with the younger manic group (3 years). McDonald and Nemeroff⁵⁴ have noted that late-onset mania may be associated with poor recognition of mood symptoms by providers, resulting in increased caregiver burden, premature nursing home placement, and a more rapid functional decline. In community settings, the MDQ has been demonstrated to be useful in identifying older adults with bipolar disorder.³ Psychiatrists and other clinicians treating depressed elderly patients must be aware of the possibility of a bipolar disorder, particularly in individuals who experience apparently treatment-refractory illness, irritability, or new-onset mood lability.

No published, evidence-based treatment guidelines have been specifically developed for geriatric bipolar disorder. In the absence of prospective, controlled treatment trials in geriatric bipolar disorder, current treatment guidelines that refer to treatment of older adults with bipolar disorder largely rely on extrapolated findings from mixed-age populations.^{46,55} A recent trial¹⁷ of standardized treatment in bipolar disorder involving geriatric patients was modeled after the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD),⁵⁶ in which the goals of medication treatment were "to maximize the ap-

propriate use of lithium or valproate (either singly or in combination), to achieve remission of acute mood episodes, maintain euthymia, and minimize adjunctive antipsychotic or antidepressant medications, except as judged clinically necessary."^{17(p320)} As with younger individuals suffering from bipolar disorder, effective treatment of underlying mood disorder is critically important, and isolated treatment of anxiety symptoms without good control of mood symptoms is likely to be difficult and unlikely to be optimally effective.

The limited data on lithium and valproate treatment in geriatric populations suggest that both of these compounds may be effective⁵⁷⁻⁶⁰; however, tolerability issues may arise, particularly in frail or debilitated elders. Neurologic adverse effects have been reported in approximately 30% of older adults treated with lithium.⁶¹⁻⁶³ Abnormal serum levels of thyroid-stimulating hormone or need for thyroid replacement have been reported in 30% of older adults taking lithium as well.⁶⁴ Additional adverse effects that may be associated with taking lithium in older adults include polyuria, polydipsia, ECG abnormalities, edema, and weight gain.⁶⁵ Valproate has frequently replaced lithium as a treatment of choice for the elderly in some practice settings,⁶⁶ but valproate may have adverse effects in the elderly as well, such as sedation, tremor, and gait disturbance.⁶⁵ Research is underway to more clearly define efficacy and tolerability of lithium versus valproate in older adult populations.⁶⁷

Current treatment choices should be informed by the safety and tolerability profiles of medication with respect to the unique profile of the individual patient.⁴⁶ Lamotrigine, a novel anticonvulsant that has demonstrated usefulness in bipolar depression, may also be effective and relatively well tolerated in older adult bipolar populations.⁶⁸ However, rigorous trials in bipolar elderly patients remain to be conducted. Carbamazepine may offer some advantage in individuals with atypical bipolar disorder⁶⁹ and may be of particular relevance in older adult populations in which bipolar symptoms secondary to neurologic illness are a greater concern.⁷⁰

The anticonvulsants topiramate⁷¹ and gabapentin⁷² have shown some benefits in the management of mixed populations with bipolar disorder and comorbid anxiety, but it is not clear what role these agents may play in the treatment of geriatric patients with bipolar disorder and anxiety. Sethi and colleagues⁷³ reported on a small case series (N = 7) in which gabapentin appeared effective in geriatric mania, with excellent tolerability. Topiramate has minimal hepatic metabolism, low protein binding, and minimal drug interactions and is excreted mostly unchanged in the urine, all features that may be advantageous for some elderly patients. However, topiramate may also have a higher incidence of cognitive adverse effects compared with some other anticonvulsants, which may be particularly problematic for older adult patients.⁷⁴

Atypical antipsychotics represent a potentially valuable treatment option for geriatric patients with bipolar disorder, particularly when compared with conventional antipsychotic agents, with which parkinsonism and tardive dyskinesia are major concerns. Secondary analyses of older bipolar adults treated with olanzapine⁷⁵ or quetiapine⁷⁶ suggest benefit and reasonably good tolerability. Case reports and retrospective studies also indicate improvement with risperidone in elderly bipolar patients,⁷⁷ and clozapine has been reported to be of benefit in refractory geriatric bipolar disorder.⁶⁶ Potential side effects of particular relevance to older adult populations include weight gain and metabolic abnormalities (particularly with clozapine and olanzapine), extrapyramidal symptoms (particularly with risperidone), anticholinergic effects (particularly with clozapine), and potential for QTc prolongation (particularly with ziprasidone).⁷⁸

Recently, the U.S. Food and Drug Administration (FDA) issued a warning of an increased risk (1.6- to 1.7-fold) of death associated with all novel antipsychotics in elderly patients with dementia-related psychosis.⁷⁹ The FDA also indicated that typical antipsychotics may carry a similar risk. Because there are no reports of increased risk of mortality with atypical antipsychotics in patients with bipolar disorder, the relevance of the FDA findings with respect to older patients with bipolar disorder is not clear.

TREATMENT OF ANXIETY SYMPTOMS AMONG OLDER ADULTS WITH BIPOLAR DISORDER

There are no published studies to our knowledge that address the management of comorbid anxiety states in late-life bipolar disorder, but some lessons learned from the treatment of mixed-age patients with comorbid anxiety and from treatment of older patients with anxious depression are likely to be helpful.

Among mixed-age individuals with bipolar disorder, divalproex may decrease generalized anxiety and panic symptoms.⁸⁰ Carbamazepine was found to be ineffective for panic disorder in one trial.⁸¹ Atypical antipsychotics have been found to be helpful for a number of anxiety disorders including PTSD, OCD, and as adjunctive treatment in GAD. Antidepressant medications, particularly selective serotonin reuptake inhibitors and other novel compounds, may be utilized for depressed bipolar patients, including older adults,⁵⁵ but issues of possible manic "switching" may be a potential complication. Among older adults with depression, tricyclic antidepressants have assumed a more limited role mainly because of relatively greater adverse effects.

A major concern for patients with anxious depression is the increased risk of early treatment withdrawal due to anxiety symptoms, leading to fear of medications, increased somatic symptoms, and rumination about mild adverse effects.³⁵ If appropriately identified, anxiety comor-

bid with mood symptoms can be effectively managed via a number of different strategies. First, a pretreatment account of the patient's physical symptoms of anxiety is often helpful for comparison with later symptoms that could be attributed to side effects.⁸² Medications should be started at the lowest possible dosage but with the same target dosage as for nonanxious patients. Physicians should discuss such potential events with patients and assuage concerns by reassuring them that they will be monitored closely and that they can reach their provider if help is needed.^{35,41} Cognitive-behavioral treatment strategies modified for anxious elderly patients^{43,83} may also be useful. Such structured support of older patients with anxious depression can achieve outcomes similar to those in patients without anxiety.⁸⁴ Structured support is likely to be of benefit to those with anxiety and bipolar disorder as well, though this potential benefit remains to be studied.

CONCLUSION

Comorbid anxiety disorders are known to be common among mixed-age populations with bipolar illness, but little information is available on comorbid anxiety among geriatric individuals with bipolar illness. Anxiety disorders may be underreported among geriatric patients with serious mental illness, including bipolar disorder. It can be expected that comorbid anxiety among older individuals with bipolar disorder is likely to increase treatment complexity and may be associated with greater symptom severity, greater chronicity, and greater functional impairment than in younger patients. Preliminary and uncontrolled reports suggest that lithium, some anticonvulsants, and some atypical antipsychotics may be of benefit for geriatric patients with bipolar disorder and comorbid anxiety, but controlled studies are needed to provide the basis for evidence-based treatment decisions.

Drug names: carbamazepine (Eptol, Tegretol, and others), clozapine (FazaClo, Clozaril, and others), divalproex (Depakote), gabapentin (Neurontin and others), lamotrigine (Lamictal), lithium (Eskalith, Lithobid, and others), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), topiramate (Topamax), ziprasidone (Geodon).

Disclosure of off-label usage: The authors have determined that, to the best of their knowledge, clozapine, gabapentin, and topiramate are not approved by the U.S. Food and Drug Administration for the treatment of bipolar disorder.

REFERENCES

1. U.S. Department of Health and Human Services, Administration on Aging. A profile of older Americans: 2001. Available at: <http://www.aoa.dhhs.gov/aoa/STATS/profie/2001/highlights.html>. Accessed March 2002.
2. Van Gerpen MW, Johnson JE, Winstead DK. Mania in the geriatric patient population: a review of the literature. *Am J Geriatr Psychiatry* 1999;7:188-202.
3. Hirschfeld R, Calabrese J, Weisman M, et al. Screening for bipolar disorder in the community. *J Clin Psychiatry* 2003;64:53-59.
4. Depp CA, Jeste DV. Bipolar disorder in older adults: a critical review.

- Bipolar Disord 2004;6:343–367
5. Sajatovic M, Blow FC, Ignacio RV, et al. New-onset bipolar disorder in later life. *Am J Geriatr Psychiatry* 2005;13:282–289
 6. Cassidy F, Carroll BJ. Vascular risk factors in late-onset mania. *Psychol Med* 2002;32:359–362
 7. Clayton PJ. The prevalence and course of the affective disorders. In: *The Affective Disorders*. Davis JM, Maas JW, eds. Washington, DC: American Psychiatric Association Press; 1983:93–201
 8. Almeida OP, Fenner S. Bipolar disorder: similarities and differences between patients with illness onset before and after 65 years of age. *Int Psychogeriatr* 2002;14:311–322
 9. Goodwin FK, Jamison KR. *Manic Depressive Illness*. Oxford, UK: Oxford University Press; 1990
 10. Moorhead SR, Young AH. Evidence for a late onset bipolar-I disorder sub-group from 50 years. *J Affect Disord* 2003;73:271–277
 11. Depp CA, Lindamer LA, Folsom DP, et al. Differences in clinical features and mental health service use in bipolar disorder across the life span. *Am J Geriatr Psychiatry* 2005;13:290–298
 12. Dhingra U, Rabins PV. Mania in the elderly: a 5–7 year follow up. *J Am Geriatr Soc* 1991;39:581–583
 13. Berrios GE, Bakshi N. Manic and depressive symptoms in the elderly: their relationships to treatment outcome, cognition, and motor symptoms. *Psychopathology* 1991;24:31–38
 14. Kessing LV, Nilsson FM. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. *J Affect Disord* 2003;73:261–269
 15. Lyketsos CG, Corazzini K, Steele C. Mania in Alzheimer's disease. *J Neuropsychiatry Clin Neurosci* 1995;7:350–352
 16. Krauthammer C, Klerman LG. Secondary mania. *Arch Gen Psychiatry* 1978;35:1333–1339
 17. Gildengers AG, Mulsant BH, Begley AE, et al. A pilot study of standardized treatment in geriatric bipolar disorder. *Am J Geriatr Psychiatry* 2005;13:319–322
 18. Reynolds CF, Frank E, Perl JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years [comments]. *JAMA* 1999;281:39–45
 19. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34–38 years. *J Affect Disord* 2002;68:167–181
 20. Angst J, Preisig M. Course of a clinical cohort of unipolar, bipolar, and schizoaffective patients: results of a prospective study from 1959 to 1985. *Schweiz Arch Neurol Psychiatr* 1995;146:7–16
 21. Flint AJ. Anxiety and its disorders in late life: moving the field forward [editorial]. *Am J Geriatr Psychiatry* 2005;13:3–6
 22. Flint AJ. Anxiety disorders. In: Sadavoy J, Jarvik LE, Grossberg GT, et al., eds. *Comprehensive Textbook of Geriatric Psychiatry*, 3rd ed. New York, NY: Norton; 2004:687–699
 23. Blazer DG, George LK, Hughes DC. The epidemiology of anxiety disorders: an age comparison. In: Salzman C, Lichowitz B, eds. *Anxiety and the Elderly*. New York, NY: Springer; 1991
 24. Hybels CF, Blazer DG. Epidemiology of late-life mental disorders. *Clin Geriatr Med* 2003;19:663–696
 25. Forsell Y, Winblad B. Feelings of anxiety and associated variables in a very elderly population. *Int J Geriatr Psychiatry* 1998;13:454–458
 26. Kvaal K, Maciejuskiene J, Engedal K, et al. High prevalence of anxiety symptoms in hospitalized geriatric patients. *Int J Geriatr Psychiatry* 2001;16:690–693
 27. Lindsay J, Briggs K, Murphy E. The Guy's/Age Concern Survey: prevalence rates of cognitive impairment, depression, and anxiety in an urban elderly community. *Br J Psychiatry* 1989;155:317–329
 28. Beekman ATF, Bremner MA, Deeg DJH, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. *Int J Geriatr Psychiatry* 1998;13:717–726
 29. Blazer D, Hughes D, George L. Generalized anxiety disorder. In: Robins L, Regier D, eds. *Psychiatric Disorders in America: the Epidemiologic Catchment Area Study*. New York, NY: The Free Press; 1991:180–203
 30. Bland RC, Newman SC, Orn H. Prevalence of psychiatric disorders in the elderly in Edmonton. *Acta Psychiatr Scand Suppl* 1988;338:57–63
 31. Sheikh JI, Swales PJ, Carlson EB, et al. Aging and panic disorder. *Am J Geriatr Psychiatry* 2004;12:102–109
 32. LeRoux H, Gatz M, Wetherell JL. Age at onset of generalized anxiety disorders in older adults. *Am J Geriatr Psychiatry* 2005;13:23–30
 33. Lenze EJ, Mulsant BH, Mohlman J, et al. Generalized anxiety in late life: lifetime course and comorbidity with major depressive disorder. *Am J Geriatr Psychiatry* 2005;13:77–80
 34. Beekman AT, de Beurs E, van Balkom AJ, et al. Anxiety and depression in later life: co-occurrence and communality of risk factors. *Am J Psychiatry* 2000;157:89–95
 35. Lenze EJ, Mulsant BH, Shear KM, et al. Anxiety symptoms in elderly patients with depression: what is the best approach to treatment? *Drugs Aging* 2002;19:753–760
 36. Gallo JJ, Rabins PV. Depression without sadness: alternative presentations of depression in late life. *Am Fam Physician* 1999;60:820–826
 37. Lenze EJ, Mulsant BH, Shear MK, et al. Comorbid anxiety disorders in depressed elderly patients. *Am J Psychiatry* 2000;157:722–728
 38. Schoevers RA, Deeg DJH, van Tilburg W, et al. Depression and generalized anxiety disorder: co-occurrence and longitudinal patterns in elderly patients. *Am J Geriatr Psychiatry* 2005;13:31–39
 39. Hegel MT, Unutzer J, Tang L, et al. Impact of comorbid panic and post-traumatic stress disorder on outcomes of collaborative care for late-life depression in primary care. *Am J Geriatr Psychiatry* 2005;13:48–58
 40. Alexopoulos GS, Katz IR, Bruce ML, et al. Remission in depressed geriatric primary care patients: a report from the PROSPECT study. *Am J Psychiatry* 2005;162:718–724
 41. Lenze EJ, Karp JF, Mulsant BH, et al. Somatic symptoms in late-life anxiety: treatment issues. *J Geriatr Psychiatry Neurol* 2005;18:89–96
 42. Lenze EJ. Comorbidity of depression and anxiety in the elderly. *Curr Psychiatry Rep* 2003;5:62–67
 43. Wetherell JL, Kaplan RM, Kallenberg G, et al. Mental health treatment preferences of older and younger primary care patients. *Int J Psychiatry Med* 2004;34:219–233
 44. Kessler RC, Rubino DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. *Psychol Med* 1997;27:1079–1089
 45. Ponce H, Kunik M, Molinari V, et al. Divalproex sodium treatment in elderly male bipolar patients. *J Geriatr Drug Ther* 1999;12:55–63
 46. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. *Bipolar Disord* 2005;7(suppl 3):5–69
 47. Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. *J Affect Disord* 2002;68:1–23
 48. Chen YW, Dilsaver SC. Comorbidity of panic disorder in bipolar illness: evidence from the Epidemiologic Catchment Area Survey. *Am J Psychiatry* 1995;152:280–282
 49. Simon NM, Smoller JW, Fava M, et al. Comparing anxiety and anxiety-related traits in bipolar and unipolar depression. *J Psychiatr Res* 2003;37:187–192
 50. US Dept of Health and Human Services, National Institute of Mental Health. *Epidemiologic catchment area survey of mental disorders, wave 1 (household), 1980–1985: [US] 2002;ICPSR 8993:1–911*
 51. Blow F. Epidemiology and health services utilization of late-life bipolar disorder. Presented at the 18th annual meeting of the American Association for Geriatric Psychiatry; March 3–6, 2005; San Diego, Calif
 52. Young RC, Klerman GL. Mania in late life: focus on age at onset. *Am J Psychiatry* 1992;149:867–876
 53. Broadhead J, Jacoby R. Mania in old age: a first prospective study. *Int J Geriatr Psychiatry* 1990;5:215–222
 54. McDonald WM, Nemeroff CB. The diagnosis and treatment of mania in the elderly. *Bull Menninger Clin* 1996;60:174–196
 55. American Psychiatric Association. *Practice Guideline for the Treatment of Patients With Bipolar Disorder [revision]*. *Am J Psychiatry* 2002;159(suppl 4):1–50
 56. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the Systematic Treatment-Enhancement Program for Bipolar Disorder (STEP-BD). *Biol Psychiatry* 2003;53:1028–1042
 57. Oshima A, Higuchi T. Treatment guidelines for geriatric mood disorders. *Psychiatry Clin Neurosci* 1999;53(suppl):S55–S59
 58. Chen ST, Altshuler LL, Melnyk KA, et al. Efficacy of lithium vs valproate in the treatment of mania in the elderly: a retrospective study. *J Clin Psychiatry* 1999;60:181–186
 59. Sanderson DR. Use of mood stabilizers by hospitalized geriatric patients with bipolar disorder. *Psychiatr Serv* 1998;49:1145–1147
 60. McFarland BH, Miller MR, Staumford E. Valproate use in the older manic patient. *J Clin Psychiatry* 1990;51:479–481

61. Himmelhoch JM, Neil JF, May SJ, et al. Age, dementia, dyskinesias, and lithium response. *Am J Psychiatry* 1980;137:941–945
62. Chacko RC, Marsh BJ, Marmion J, et al. Lithium side effects in elderly bipolar outpatients. *Hillside J Clin Psychiatry* 1987;9:79–88
63. Smith RE, Helms PM. Adverse effects of lithium therapy in the acutely ill elderly patient. *J Clin Psychiatry* 1982;43:94–99
64. Roose SP, Bone S, Haidorfer C, et al. Lithium treatment in older patients. *Am J Psychiatry* 1979;136:843–844
65. Sajatovic M, Madusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. *Drugs Aging* 2005; 22:39–54
66. Shulman KI, Rochon P, Sukkora K, et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. *BMJ* 2003;326:960–961
67. Young RC. A randomized controlled trial of acute treatments in late-life mania. Presented at the 6th International Congress on Bipolar Disorder; June 16–18, 2005; Pittsburgh, Pa
68. Sajatovic M, Gyulai L, Calabrese JR, et al. Maintenance treatment outcomes in older patients with bipolar I disorder. *Am J Geriatr Psychiatry* 2005;13:305–311
69. Greil W, Kleindiest N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. *J Clin Psychopharmacol* 1998;18:455–460
70. Evans DL, Byerly MJ, Greer RA. Secondary mania: diagnosis and treatment. *J Clin Psychiatry* 1995;56(suppl 3):31–37
71. Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26:1035–1039
72. Vieta E, Martinez-Aran A, Nieto E, et al. Adjunctive gabapentin treatment of bipolar disorder. *Eur Psychiatry* 2000;15:433–437
73. Sethi MA, Mehta R, Devanand DP. Gabapentin in geriatric mania. *J Geriatr Psychiatry Neurol* 2003;16:117–120
74. Leppik IE. Issues in the treatment of epilepsy. *Epilepsia* 2001;42 (suppl 4):1S–6S
75. Beyer JL, Siegal A, Kennedy JS, et al. Olanzapine, divalproex, and placebo treatment, non-head to head comparisons of older adult acute mania. Presented at the 53rd Institute on Psychiatric Services; Oct 10–14, 2001; Orlando, Fla
76. Sajatovic M, Mullen J, Calabrese J. Quetiapine for the treatment of mania in older adults. Presented at the 6th annual International Congress on Bipolar Disorder; June 16–18, 2005; Pittsburgh, Pa
77. Madhusoodanan S, Suresh P, Brenner R, et al. Experience with the atypical antipsychotics risperidone and olanzapine in the elderly. *Ann Clin Psychiatry* 1999;11:113–118
78. Gardner DM, Baldessarini RJ, Warch P. Modern antipsychotic drugs: a critical overview. *CMAJ* 2005;172:1703–1711
79. FDA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients (FDA Talk Paper). Rockville, Md: US Food and Drug Administration; 2005. Available at: <http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01350.html>. Accessibility verified Nov 10, 2005
80. Lum M, Fontaine R, Elie R, et al. Probable interaction of sodium divalproex with benzodiazepines. *Prog Neuropsychopharmacol Biol Psychiatry* 1991;15:269–273
81. Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. *Am J Psychiatry* 1988;145:1104–1109
82. Stanley MA, Diefenbach GJ, Hopko DR. Cognitive behavioral treatment for older adults with generalized anxiety disorder: a therapist manual for primary care settings. *Behav Modif* 2004;28:73–117
83. Mohlman J. Psychosocial treatment of late-life generalized anxiety disorder: current status and future directions. *Clin Psychol Rev* 2004;24: 149–169
84. Lenze EJ, Mulsant BH, Dew MA, et al. Good treatment outcomes in late-life depression with comorbid anxiety. *J Affect Disord* 2003;77:247–254